Machine Learning Risk Prediction for Incident Heart Failure in Patients With Atrial Fibrillation

Yasuhiro Hamatani, MD, PhD,a Hidehisa Nishi, MD, PhD,b Moritake Iguchi, MD, PhD,a Masahiro Esato, MD, PhD,c Hikari Tsuji, MD, PhD,d Hiromichi Wada, MD, PhD,e Koji Hasegawa, MD,e Hisashi Ogawa, MD,a Mitsuru Abe, MD, PhD,a Shunichi Fukuda, MD, PhD,f Masaharu Akao, MD, PhD,a on behalf of the Fushimi AF Registry Investigators

ABSTRACT

BACKGROUND Atrial fibrillation (AF) increases the risk of heart failure (HF); however, little focus is placed on the risk stratification for, and prevention of, incident HF in patients with AF.

OBJECTIVES This study aimed to construct and validate a machine learning (ML) prediction model for HF hospitalization in patients with AF.

METHODS The Fushimi AF Registry is a community-based prospective survey of patients with AF in Fushimi-ku, Kyoto, Japan. We divided the data set of the registry into derivation (n = 2,383) and validation (n = 2,011) cohorts. An ML model was built to predict the incidence of HF hospitalization using the derivation cohort, and predictive ability was examined using the validation cohort.

RESULTS HF hospitalization occurred in 606 patients (14%) during a median follow-up period of 4.4 years in the entire registry. Data of transthoracic echocardiography and biomarkers were frequently nominated as important predictive variables across all 6 ML models. The ML model based on a random forest algorithm using 7 variables (age, history of HF, creatinine clearance, cardiothoracic ratio on x-ray, left ventricular [LV] ejection fraction, LV end-systolic diameter, and LV asynergy) had high prediction performance (area under the receiver operating characteristics curve [AUC]: 0.75) and was significantly superior to the Framingham HF risk model (AUC: 0.67; P < 0.001). Based on Kaplan-Meier curves, the ML model could stratify the risk of HF hospitalization during the follow-up period (log-rank; P < 0.001).

CONCLUSIONS The ML model revealed important predictors and helped us to stratify the risk of HF, providing opportunities for the prevention of HF in patients with AF. (JACC: Asia 2022;2:706–716) © 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
proportion of deaths in contemporary patients with AF. However, many studies have focused on the prevention of thromboembolism, and little attention has been placed on the risk stratification for, and prevention of, HF despite its high prevalence and poor prognostic impact in patients with AF. An important step toward HF prevention is to identify patients who have a high risk for the disease. Therefore, comprehensive risk stratification of incident HF is warranted for the management of AF in daily practice; however, there is a scarcity of published reports regarding these issues.

Machine learning (ML) is a subset of artificial intelligence in which algorithms learn from data without explicit programming. ML techniques provide a powerful tool for learning complex relationships between the risk predictors and clinical outcomes from a representative sample of patients. Besides, ML can efficiently process huge multi-categorical data, including biological, clinical, and imaging data, to predict the clinical outcomes.

Recent studies, including ours, revealed that ML models can achieve higher prediction performance for thromboembolism than the validated risk score, the CHA2DS2-VASc score, in patients with AF. We consider ML techniques promising for risk prediction of future HF events; however, risk stratification for HF using ML algorithms in patients with AF has not been investigated.

Accordingly, the aim of the present study was to construct an ML model for predicting the incidence of HF events and to validate its performance using the data from a large-scale community-based prospective survey of Japanese AF patients, the Fushimi AF Registry.

**METHODS**

**DATA SOURCE.** The Fushimi AF Registry is a community-based multicenter prospective observational survey of patients with AF who visited the participating medical institutions in Fushimi-ku, Kyoto, Japan. The detailed study design, patient enrollment, and definition of the measurements of the registry were previously described (UMIN000005834). Briefly, the inclusion criterion for the registry is the documentation of AF on 12-lead electrocardiography or Holter monitoring at any time. There were no exclusion criteria. A total of 81 institutions, all of which are members of the Fushimi Medical Association, participated in the registry. The participating institutions comprised 2 cardiovascular centers, 10 small and medium-sized hospitals, and 69 primary care clinics. We started to enroll patients in March 2011, and enrollment ended in May 2017. All of the participating institutions attempted to enroll all consecutive patients with AF under regular outpatient care or admission. Collection of the follow-up information was mainly conducted through review of the medical records, and additional follow-up information was collected through contact with patients, relatives, and/or referring physicians by mail or telephone.

Data of the patients were registered in the Internet Database System by the doctors in charge at each institution. Data were automatically checked for missing or contradictory entries and values out of the normal range. Additional editing and checks for duplicated records were performed by clinical research coordinators at the general office of the registry. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethical committees of the National Hospital Organization Kyoto Medical Center (10-058) and Ijinkai Takeda Hospital (14-033).

**OUTCOMES.** The primary endpoint in this study was the incidences of hospitalization for HF during the follow-up period. HF hospitalization was determined by the attending physicians based on history, clinical presentation (symptoms and physical examinations), natriuretic peptide levels, imaging findings including chest x-ray and echocardiography, cardiac catheterization findings, response to HF therapy, and in-hospital course. We continued follow-up until the death endpoint, and we defined clinical outcomes as the time to first event.

**DATA PROCESSING.** For the purpose of creating and validating the ML model, we divided the entire cohort of the registry into a derivation cohort and validation cohort. The data of patients from 1 cardiovascular center and half of the small and medium-sized hospitals and primary care clinics, which were randomly selected, were assigned as the derivation cohort. The data of patients from the other cardiovascular center and the remaining half of hospitals and primary care clinics were assigned as the validation cohort.

The data included baseline patient characteristics, oral prescription, the results of blood tests, and imaging data derived from chest x-ray and transthoracic echocardiography at registration. A total of 168 baseline variables were included in the data set of the Fushimi AF Registry. For data preprocessing, variables that were not clinically meaningful (for example, enrollment date) were deleted at the investigators’ discretion based on the clinical
**TABLE 1 Patient Characteristics and Clinical Outcomes**

|                                | Derivation Cohort (n = 2,383) | Validation Cohort (n = 2,011) | P Value |
|--------------------------------|-------------------------------|-------------------------------|---------|
| **Baseline characteristics**   |                               |                               |         |
| Age, y                         | 73.8 ± 10.8                   | 73.3 ± 10.9                   | 0.20    |
| Female                         | 933 (39)                      | 832 (41)                      | 0.13    |
| Body mass index, kg/m²         | 23.2 ± 4.2                    | 23.0 ± 3.8                    | 0.14    |
| Body weight, kg                | 59.6 ± 13.8                   | 59.2 ± 13.1                   | 0.37    |
| Systolic blood pressure, mmHg  | 125 ± 18                      | 125 ± 20                      | 0.97    |
| Pulse rate, beats/min          | 80 ± 17                       | 77 ± 15                       | <0.001  |
| Paroxysmal AF                  | 1,055 (44)                    | 1,139 (57)                    | <0.001  |
| Smoking history                | 969 (54)                      | 522 (41)                      | <0.001  |
| **Baseline characteristics**   |                               |                               |         |
| **History**                    |                               |                               |         |
| Pre-existing HF                | 700 (29)                      | 504 (25)                      | 0.001   |
| History of stroke/SE           | 502 (21)                      | 381 (19)                      | 0.081   |
| Coronary artery disease        | 335 (14)                      | 309 (15)                      | 0.22    |
| Valvular heart disease         | 440 (18)                      | 317 (16)                      | 0.018   |
| Cardiomyopathy                 | 59 (2)                        | 63 (3)                        | 0.19    |
| Hypertension                   | 1,609 (68)                    | 1,164 (58)                    | <0.001  |
| Dyslipidemia                   | 978 (41)                      | 965 (48)                      | <0.001  |
| Diabetes mellitus              | 600 (25)                      | 437 (22)                      | 0.007   |
| Peripheral artery disease      | 108 (5)                       | 70 (3)                        | 0.078   |
| Chronic kidney disease         | 943 (40)                      | 640 (32)                      | <0.001  |
| COPD                           | 132 (6)                       | 100 (5)                       | 0.40    |
| History of major bleeding      | 104 (4)                       | 94 (5)                        | 0.62    |
| **Baseline characteristics**   |                               |                               |         |
| **Biomarkers**                 |                               |                               |         |
| Oral antiocoagulants           | 1,258 (53)                    | 1,168 (59)                    | <0.001  |
| Warfarin                       | 893 (38)                      | 896 (45)                      | <0.001  |
| DOAC                           | 365 (15)                      | 272 (14)                      | 0.13    |
| ACE-I/ARBs                     | 1,133 (48)                    | 814 (41)                      | <0.001  |
| Loop diuretics                 | 674 (28)                      | 676 (34)                      | <0.001  |
| **Baseline characteristics**   |                               |                               |         |
| **Chest x-ray data**           |                               |                               |         |
| Cardio-thoracic ratio, %       | 54 ± 7                        | 55 ± 7                        | <0.001  |
| **Baseline characteristics**   |                               |                               |         |
| **Echocardiographic data**     |                               |                               |         |
| LV end-diastolic diameter, mm  | 46.5 ± 6.5                    | 46.6 ± 6.2                    | 0.57    |
| LV end-systolic diameter, mm   | 31.0 ± 6.8                    | 30.0 ± 6.7                    | <0.001  |
| LV ejection fraction, %        | 61.4 ± 11.8                   | 64.7 ± 11.2                   | <0.001  |
| LV asynergy                    | 420 (21)                      | 354 (23)                      | 0.11    |
| Left atrial diameter, mm       | 43.1 ± 8.2                    | 44.0 ± 8.2                    | 0.002   |
| **Clinical outcomes**          |                               |                               |         |
| Hospitalization for HF         | 378 (16)                      | 228 (11)                      | <0.001  |
| All-cause death                | 631 (26)                      | 355 (18)                      | <0.001  |
| Follow-up period, y            | 4.0 (2.0-7.0)                 | 5.0 (2.1-7.4)                 | <0.001  |

Values are mean ± SD, n (%), or median (IQR).

ACE-I = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker; BNP = B-type natriuretic peptide; COPD = chronic obstructive pulmonary disease; CrCl = creatinine clearance; DOAC = direct oral anticoagulants; HF = heart failure; LV = left ventricular; NT-proBNP = N-terminal pro-B-type natriuretic peptide; SE = systemic embolism.
imputation process, all other variables in the validation cohort were used to create imputed results. Model performance metrics were displayed with 95% confidence intervals using 2,000 iterations of bootstrap.

Subsequently, we created a practical ML model using several variables with a view of future applicability. Inasmuch as there are no clear criteria for variable selection, we extracted several variables based on validity, feasibility, and applicability from the clinician’s perspective. Considering the SHAP value and the comparable predictive ability across each ML model, we finally selected 7 variables in the random forest algorithm for the practical ML model. Then, 6 ML algorithms using these 7 variables were also evaluated for performance using the validation cohort. Thereafter, we compared the receiver operating characteristics curve based on the random forest algorithm using 7 variables with that of the Framingham HF risk model.20 Given that there is no validated risk model for predicting incident HF among patients with AF, we adopted the Framingham HF risk model, which is considered to be the most famous HF risk model for patients with cardiovascular diseases. We defined left ventricular (LV) hypertrophy as interventricular septum thickness ≥12 mm instead of the electrocardiogram criteria in the original model.20 The Kaplan-Meier curves were plotted to display the clinical course among the subgroups stratified by the random forest algorithm using 7 variables in the validation cohort. The distribution of the predicted probability was divided into tertiles: low risk was defined as probability in the first tertile, intermediate risk as probability in the second tertile, and high risk as probability in the top tertile. Last, we specifically examined the predictive performance of practical ML models among patients without pre-existing HF in the validation cohort.

STATISTICAL ANALYSIS. Continuous variables are presented as the mean ± SD when normally distributed, and as the median and interquartile range when non-normally distributed. Distribution was assessed using histograms. The Kaplan-Meier method was used to estimate the cumulative incidences of clinical outcomes, and log-rank testing was performed to assess differences among groups. The hazard ratio of the events was calculated using the Cox proportional hazards model. Receiver operating characteristics curves were compared using the Henley and McNeil method.21 All statistical tests were 2-tailed, and a value of $P < 0.05$ was considered significant. All analyses were performed using JMP version 14.2.0 (SAS Institute) and R statistical software version 4.0.0.

---

### RESULTS

#### BASELINE CHARACTERISTICS

We obtained a total of 4,396 patients with follow-up data by April 2019. We excluded 2 patients without the data of HF hospitalization during the follow-up period. Of the 4,394 patients, the mean age was $73.6 \pm 10.9$ years, and 1,765 (40%) were female. Paroxysmal AF accounted for 2,194 (50%) patients, and 1,204 (27%) patients had pre-existing HF. In total, the derivation cohort and the validation cohort included the data for 2,383 and 2,011 patients, respectively. The patients’

---

### TABLE 2 Performances of 6 Machine Learning Models Using All Variables in the Validation Cohort

| Machine Learning Model | Sensitivity | Specificity | Accuracy | AUC   |
|------------------------|-------------|-------------|----------|-------|
| Random forest          | 65.8 ± 1.2  | 73.0 ± 0.4  | 72.0 ± 0.3 | 0.77 ± 0.00 |
| Light gradient boosting machine | 67.1 ± 1.1  | 72.7 ± 0.5  | 72.0 ± 0.3 | 0.77 ± 0.01 |
| Elastic net            | 68.6 ± 1.5  | 71.6 ± 0.6  | 71.4 ± 0.6 | 0.77 ± 0.01 |
| Linear support vector machine | 68.0 ± 1.0  | 72.3 ± 0.5  | 71.7 ± 0.4 | 0.76 ± 0.00 |
| Neural network         | 59.6 ± 1.4  | 77.2 ± 0.4  | 75.2 ± 0.4 | 0.77 ± 0.01 |
| Naive Bayes            | 57.2 ± 1.4  | 80.1 ± 0.4  | 77.4 ± 0.5 | 0.78 ± 0.00 |

AUC = area under the curve.
characteristics in the derivation and validation cohorts are presented in Table 1. Patients in the derivation cohort had a lower prevalence of paroxysmal AF and dyslipidemia and had a higher prevalence of pre-existing HF, hypertension, diabetes mellitus, and chronic kidney disease (all \( P < 0.05 \)). Oral anticoagulants were less frequently prescribed, and cardiothoracic ratio and LV ejection fraction were lower in patients in the derivation cohort than in those in the validation cohort (all \( P < 0.05 \)) (Table 1).

**CLINICAL OUTCOMES.** During a median follow-up period of 4.4 years (IQR: 2.1-7.0 years), a total of 606 (14%) hospitalizations for HF occurred among the entire 4,394 patients at a rate of 3.3% per person-year. The Kaplan-Meier curve for the incidence of HF hospitalization is shown in Supplemental Figure 1. The annual incidence rate of HF hospitalization in the derivation cohort was 4.0% per person-year, and that in the validation cohort was 2.5% per person-year. All-cause death occurred in 986 (22%) of 4,394 patients.
patients, and the annual mortality rate was 6.1% in the derivation cohort and 3.7% in the validation cohort.

**PERFORMANCE OF ML MODEL.** The algorithm performance (sensitivity, specificity, accuracy, and AUC) of each ML model using all variables in the derivation cohort are presented in Supplemental Table 3. All 6 models had comparable high predictive performance (AUC range: 0.77-0.83). The performance metrics of the 6 ML models using the validation cohort are shown in Table 2 and Figure 1. Briefly, each ML model had high sensitivity, specificity, and accuracy. The AUCs for each model were also high (range: 0.76-0.78) using the validation cohort.

**IMPORTANT VARIABLES OF EACH ML MODEL.** After calculation of the importance of each variable, the top 10 important variables in each ML model are shown in Figure 2. Pre-existing HF was the most important variable across all 6 ML models. Trans-thoracic echocardiography data, such as LV ejection fraction, LV diameter, presence of LV asynergy, and left atrial diameter, were frequently included in the top 10 variables in each model. Age, uric acid, and renal function, represented by creatinine clearance, blood urea nitrogen, creatinine, and history of chronic kidney disease were in the top 10 variables in almost all models. Other histories that are common causes of HF, such as hypertension, valvular heart disease, and coronary artery disease, were also included in several ML models.

**PRACTICAL RISK PREDICTION MODEL USING ML ALGORITHMS.** We extracted the top 7 variables in the random forest algorithm based on their clinical validity, feasibility, and applicability (age, pre-existing HF, LV ejection fraction, LV end-systolic diameter, LV asynergy, creatinine clearance, and cardiothoracic ratio on chest x-ray) (Figure 2).

The predictive performances of each practical ML model using the 7 variables for the validation cohort are shown in Table 3. The AUCs of the 6 ML algorithms using these 7 variables for the validation cohort are shown in Figure 3A. The AUCs for each model were high (range: 0.73-0.75) using the validation cohort. The AUC of the Framingham HF risk model for the validation cohort is shown in Figure 3B. According to the Hanley and McNeil method, the ML model with random forest algorithm using the 7 variables was

### Table 3 Performances of 6 Machine Learning Models Using 7 Variables in the Validation Cohort

| Machine Learning Model           | Sensitivity | Specificity | Accuracy | AUC    |
|---------------------------------|-------------|-------------|----------|--------|
| Random forest                   | 67.2 ± 1.6  | 71.3 ± 1.1  | 71.0 ± 0.4 | 0.75 ± 0.01 |
| Light gradient boosting machine | 72.0 ± 1.0  | 65.0 ± 0.6  | 65.9 ± 0.4 | 0.75 ± 0.00 |
| Elastic net                     | 68.0 ± 1.0  | 71.7 ± 0.5  | 71.0 ± 0.6 | 0.75 ± 0.01 |
| Linear support vector machine   | 68.1 ± 1.0  | 71.7 ± 0.5  | 71.1 ± 0.6 | 0.75 ± 0.01 |
| Neural network                  | 68.9 ± 1.1  | 72.0 ± 0.5  | 71.7 ± 0.5 | 0.75 ± 0.01 |
| Naive Bayes                     | 35.8 ± 1.0  | 89.0 ± 0.4  | 83.0 ± 0.4 | 0.73 ± 0.01 |

The 7 variables include age, pre-existing heart failure, creatinine clearance, cardiothoracic ratio on chest x-ray, left ventricular ejection fraction, left ventricular end-systolic diameter, and left ventricular asynergy. AUC = area under the curve.

### Figure 3 ROC Curves of the Risk Models for the Validation Cohort

(A) Practical ML models using 7 variables. (B) Framingham HF risk model. The 7 variables include age, pre-existing HF, creatinine clearance, cardiothoracic ratio on x-ray, LV ejection fraction, LV end-systolic diameter, and LV asynergy. AUC = area under the curve; GBM = gradient boosting machine; HF = heart failure; LV = left ventricular; ML = machine learning; ROC = receiver operating characteristic; SVM = support vector machine.
significantly superior to the Framingham HF risk model (AUC: 0.75 vs. 0.67; \(P < 0.001\)). The practical ML model was able to stratify the risk of HF hospitalization among patients without pre-existing HF (log-rank; \(P < 0.001\)) (Figure 5A, Supplemental Table 5). High-risk patients had a 6-fold higher risk (HR: 5.97; 95% CI: 3.42-10.44; \(P < 0.001\)), and intermediate risk patients had a 3-fold higher risk of HF hospitalization (HR: 3.14; 95% CI: 1.89-5.23; \(P < 0.001\)) than did low-risk patients.

DISCUSSION

In the present study, we explored the risk factors and prediction model using ML techniques, and we revealed the following: First, we demonstrated that ML models have a high predictive performance for the incidence of HF hospitalization in patients with AF. Second, transthoracic echocardiographic data and biomarkers were important variables for predicting future HF events. Third, the practical ML model using simple and readily available variables showed a higher predictive ability than did the pre-existing HF risk model and was able to stratify the risk of HF hospitalization among patients with AF (Central Illustration).

RISK PREDICTION FOR INCIDENT HF IN PATIENTS WITH AF. AF and HF are closely linked and often develop concurrently, with each disease predisposing patients to the other. HF now represents the most common cardiovascular complication in patients with AF, developing at a rate nearly twice that of stroke.2,3 Of note, the incidence of HF did not significantly change over a period of decades despite significant advances in the treatment of patients with AF, developing at a rate nearly twice that of stroke.4,5 In addition to being frequent, incident HF is associated with a high mortality. Once patients with AF experience HF, they have a risk of mortality that is approximately 2- to 3-fold higher than that of those without.2,22,24-26 These findings underscore the importance of risk stratification for, and prevention of, incident HF in patients with AF.

Several studies have evaluated the significant predictors of incident HF among patients with AF. The ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) reported that significant predictors for incident HF were advanced age, coronary artery disease, valvular heart disease, renal dysfunction, heart rate, and permanent type of AF.25 In the United States Women's Health Study, well-established modifiable HF risk factors, such as diabetes mellitus and body mass index, were independently associated with the increased risk of

AMONG PATIENTS WITHOUT PRE-EXISTING HF. Of 2,011 patients in the validation cohort, 1,507 patients did not have pre-existing HF. Even among patients without pre-existing HF, the practical ML model had a certain level of predictive ability...
HF development in AF. A few risk prediction scores for incident HF have also been investigated; however, these previous studies used simple standard statistical models like Cox regression analysis with inherent limitations, including correlation between variables, nonlinearity of variables, and limit of the variable number included in the model. By contrast, ML techniques can overcome these limitations. All ML risk prediction models evaluated in this study had a high predictive performance (AUC: 0.76-0.78), as shown in Table 2 and Figure 1, for predicting hospitalization for HF. ML techniques are expected to be the basis of risk stratification for future HF events in patients with AF.

BIOMARKER AND ECHOCARDIOGRAPHY FOR RISK PREDICTION OF HF. This study was unique in that it clarified predictors among data comprising >100 variables, including biological data, histories, biomarkers, and imaging data, using ML algorithms. ML provides the opportunity of discovering new predictors that are not hypothesis driven and without prior assumptions. Previous studies mainly included variables related to the patients’ backgrounds and comorbid conditions, and they were unable to address the importance of biomarkers and imaging data. Of note, our ML model suggested that imaging data and biomarkers are important variables for predicting incident HF, revealed by their prominent presence on the list of top 10 variables shown in Figure 2.

Indeed, the Belgrade AF Study reported that mild left atrial dilatation or low-normal LV ejection fraction in structurally normal heart heralds an increased risk of incident HF. Another study reported that increased left atrial volume provided prognostic information for the prediction of HF events in AF. When these previous studies are combined with ours, transthoracic echocardiography plays an important role in risk stratification for incident HF in patients with AF. In addition to imaging data, our study suggested that biomarkers can help identify patients with AF who are at an increased risk of HF events. We previously demonstrated that natriuretic peptide levels are a useful biomarker for the risk stratification of HF hospitalization in patients with AF, although this biomarker was unable to be included in our ML models because of missing data. Biomarkers of inflammation, kidney function, and hemoglobin levels were also reportedly associated with a higher incidence of HF in these patients. However, there is a scarcity of studies incorporating imaging data and biomarkers for the risk prediction model of HF events. Our ML models using these imaging and biomarker data had a high predictive ability, which suggests the utility of incorporating these data for risk stratification for incident HF in patients with AF.
IMPLICATION OF ML RISK PREDICTION MODELS IN CLINICAL PRACTICE. Some burdens are specific to the application of ML models in daily practice. In particular, risk stratification using dozens of variables is difficult or almost impossible to implement in clinical practice. Therefore, we ultimately selected several variables for risk prediction with a view to their future practicality. A practical ML model incorporating only 7 variables (age, pre-existing HF, renal function, cardiothoracic ratio, and echocardiographic LV parameters) has the potential to become an appropriate risk prediction tool for future HF events among patients with AF. Objective data for these 7 variables are easy to obtain, and we believe that our ML model can be readily available in clinical practice. Of note, a random forest model using these 7 variables was shown to have a higher predictive ability than the Framingham HF risk model (Figure 3). Even among patients without pre-existing HF, our practical ML model was able to stratify the risk of hospitalization for heart failure in patients with atrial fibrillation. HF — heart failure; LV — left ventricular.
inhibitors, was reported to aid in preventing HF development in selected patients with AF. However, it may not be practical to give these therapies to all patients with AF, considering the inherent complications, procedural costs, and large target number. To effectively prevent the development of HF in patients with AF, it is important to identify high-risk patients as a first step. By establishing a risk prediction model using techniques like ML algorithms, studies addressing whether these interventions can prevent the incidence of HF in high-risk patients are warranted in the future.

**STUDY LIMITATIONS.** The present study has several limitations. First, this was an observational study and provides only associative evidence, not causative. Second, some potential important variables were excluded because of a large number of missing values. Indeed, two thirds of patients without pre-existing HF had no data for natriuretic peptide levels in the registry. However, we specifically clarified their prognostic significance for future HF events, highlighting the importance of measuring natriuretic peptide levels in all patients with AF. In addition, we did not collect detailed echocardiographic data, including diastolic dysfunction and biomarkers such as troponin levels in this registry. We may further increase the predictive ability of the risk algorithm for incident HF with additional measures. Third, even though we show the predictive ability of clinically available 7 variables, it is plausible that the optimal number of variables is different. In addition, chest x-ray and echocardiography might not be available for all patients with AF, especially in primary care clinics. Fourth, ML models are at high risk of overfitting, and overfitting can be truly assessed only in external data. Although our ML model demonstrated good discrimination ability in the registry, external validation is strongly warranted. Inasmuch as we used a single community-based registry, external sampling in a completely separate population is desirable. Fifth, we did not obtain echocardiographic data at HF hospitalization, and incident HF could not be classified according to LV ejection fraction. Considering these limitations, further studies are warranted to create more accurate ML risk prediction models incorporating additional important variables with external validation. We hope that our study, which suggests the utility of the ML model, forms a foundation for the prediction of HF events in patients with AF.

**CONCLUSIONS**

ML algorithms had a high predictive performance for HF hospitalization in patients with AF. Imaging data and biomarkers were important variables across all ML models, which suggests their utility for risk prediction of HF events. Our ML model using 7 simple and readily available variables was able to stratify the risk of hospitalization for HF in patients with AF, providing opportunities for the implementation of strategies to prevent HF among patients with AF.

**ACKNOWLEDGMENTS** The authors thank the clinical research coordinators (T. Shinagawa, M. Mitamura, M. Fukahori, M. Kimura, M. Fukuyama, C. Kamata, and N. Nishiyama) for their efforts.

**FUNDING SUPPORT AND AUTHOR DISCLOSURES**

The Fushimi AF Registry is supported by research funding from Boehringer Ingelheim, Bayer Healthcare, Pfizer, Bristol-Myers Squibb, Astellas Pharma, AstraZeneca, Daiichi Sankyo, Novartis Pharma, MSD, Sanofi-Aventis, and Takeda Pharmaceutical. The sponsors had no role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. This study was partially supported by the Practical Research Project for Life-Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus from Japan Agency for Medical Research and Development, AMED (19ek0210056h0003, 18ek0210056h0003). Dr Akao has received lecture fees from Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Bayer Healthcare, and Daiichi-Sankyo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

**ADDRESS FOR CORRESPONDENCE:** Dr Masaharu Akao, Department of Cardiology, National Hospital Organization Kyoto Medical Center, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan. E-mail: akao@kuhp.kyoto-u.ac.jp.

**PERSPECTIVES**

**COMPETENCY IN MEDICAL KNOWLEDGE:** ML revealed that the data of transthoracic echocardiography and biomarkers were important predictors for HF hospitalization in patients with AF. The ML model incorporating these several variables can stratify the risk of HF among patients with AF in daily practice.

**TRANSLATIONAL OUTLOOK:** Further studies are needed to create more accurate risk prediction models incorporating additional important variables, and to investigate the efficacy of pharmacological and/or non-pharmacological therapies for preventing HF events in high-risk patients with AF.
REFERENCES

1. Ohtaya A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: Systematic review and meta-analysis. BMJ. 2016;354:i4482.

2. Ninni S, Lemesle G, Meurice T, Tricot O, Lamlion N, Bauters C. Relative importance of heart failure events compared to stroke and bleeding in AF patients. J Clin Med. 2021;10:923.

3. Piccini JP, Hammill BG, Sinner MF, et al. Clinical course of atrial fibrillation in older adults: The importance of cardiovascular events beyond stroke. Eur Heart J. 2014;35:250-256.

4. Gomez-Dutes A, Laguna-Ruiz J, Terlera-Fernandez AI, Calvo-Rojas G, Suarez-Gea ML, Vargas-Castrillon E. Causes of death in anti-coagulated patients with atrial fibrillation. J Am Coll Cardiol. 2016;68:2508-2521.

5. An Y, Ogawa H, Yamashita Y, et al. Causes of death in Japanese patients with atrial fibrillation: The Fushimi atrial fibrillation registry. Eur Heart J Qual Care Clin Outcomes. 2019;5:35-42.

6. Cai A, Zhu Y, Clarkson SA, Feng Y. The use of integrated machine learning: The multi-ethnic study of atherosclerosis. Eur J Heart Fail. 2017;19:160-172.

7. Ambale-Venkatesh B, Yang X, Wu CO, et al. Cardiovascular event prediction by machine learning: The multi-ethnic study of atherosclerosis. Circ Res. 2017;121:1092-1101.

8. Nishi H, Oishi N, Isih A, et al. Predicting clinical outcomes of large vessel occlusion before mechanical thrombectomy using machine learning. Stroke. 2019;50:2379-2388.

9. Nishi H, Oishi N, Isih A, et al. Deep learning-derived high-level neuroimaging features predict clinical outcomes for large vessel occlusion. Stroke. 2020;51:1484-1492.

10. Han L, Askari M, Altman RB, et al. Atrial fibrillation burden signature and near-term prediction of stroke: A machine learning analysis. Circ Cardiovasc Qual Outcomes. 2019;12:e005595.

11. Li X, Liu H, Du X, et al. Integrated machine learning approaches for predicting ischemic stroke and thromboembolism in atrial fibrillation. AMIA Annu Symp Proc. 2017;2016:799-807.

12. Nishi H, Oishi N, Ogawa H, et al. Predicting cerebral infarction in patients with atrial fibrillation using machine learning: The Fushimi AF registry. J Cereb Blood Flow Metab. 2022;42:746-756.

13. Akao M, Chun YH, Wada H, et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF registry. J Cardiol. 2013;61:260-266.

14. Akao M, Chun YH, Esato M, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014;78:2166-2172.

15. Jaeger BC, Cantor R, Shihnam V, Xie R, Kirklin JK, Rudraraju R. Improving outcome predictions for patients receiving mechanical circulatory support by optimizing imputation of missing values. Circ Cardiovasc Qual Outcomes. 2021;14:e007071.

16. Chen R, Stewart WF, Sun J, Ng K, Yan X. Recurrent neural networks for early detection of heart failure from longitudinal electronic health record data: Implications for temporal modeling with respect to time before diagnosis, data density, data quantity, and data type. Circ Cardiovasc Qual Outcomes. 2019;12:e005114.

17. Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. Adv Neural Inf Process Syst. 2017;4765-4774.

18. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: Seven steps for development and an ABCD for validation. Eur Heart J. 2014;35:1925-1931.

19. Aloisio KM, Swanson SA, Micali N, Field A, Horton NJ. Analysis of partially observed clustered data using generalized estimating equations and multiple imputation. Stat J. 2014;14:863-883.

20. Kannell WB, D’Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159:1197-1204.

21. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.

22. Miyasaki Y, Barnes ME, Gersh BJ, et al. Incidence and mortality risk of congestive heart failure: Results from the CABANA trial. Circulation. 2013;127:1087-1093.

23. Benz AP, Aeschbacher S, Krissi P, et al. Biomarkers of inflammation and risk of hospitalization for heart failure in patients with atrial fibrillation. J Am Coll Cardiol. 2020;76:101-105.

24. Carrero JJ, Trevisan M, Evans M, Sivmehn E, Snummer K. Kidney function and the risk of heart failure in patients with new-onset atrial fibrillation. Int J Cardiol. 2020;320:101-105.

25. Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: Results of the CABANA trial. Circulation. 2021;143:1377-1390.

26. Böhler M, Slawik J, Brueckmann M, et al. Efficiency of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: Data from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2020;22:126-135.

KEY WORDS atrial fibrillation, heart failure, machine learning, risk prediction

APPENDIX For a supplemental figure and tables, please see the online version of this paper.